ECCMID 2021 – Pfizer-sponsored anti-infectives symposia programme ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 
Having trouble viewing this email? View in your browser.

Integrated symposia at the 31st European Congress of Clinical Microbiology and Infectious Diseases, 2021

Pfizer-sponsored anti-infectives symposia programme at ECCMID 2021

Pfizer is pleased and proud to support the 31st meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). We are sponsoring a full programme of virtual symposia dedicated to infectious diseases, which will take place throughout the congress. You can find details of our ECCMID 2021 programme outlined below.

If you have not yet registered for ECCMID and would like to do so, please follow the link:

Click here to register for ECCMID 2021

Friday 09 July, 2021, 16:15–17:45 CEST

The role of patients in infectious disease research – from study participants to scientific partners 

16:15–16:22

Welcome and introduction

Chair – Nikhil Wagle (USA)
ESCMID-appointed Chair – Daniel Diekema (USA)

16:22–16:25

Our commitment to patients and infectious disease
Pol Vandenbroucke (USA)

16:25–16:35

An emerging science – making the case for patient-partnered research
Nikhil Wagle (USA)

16:35–16:45

Finding funding – how foundations can facilitate patient-partnered research
Gemma Buckland Merrett (UK)

16:45–16:55

Patient-partnered publications – the journals’ perspective
Amy Price (USA)

16:55–17:05

From concept to action – case study of patient participation in research (EKPF)
Daniel Gallego (Spain)

17:05–17:15

From concept to action – case study of patient participation in research (IAPO)
Neda Milevska Kostova (Macedonia)

17:15–17:25

From concept to action – case study of patient participation in research (Sepsis Alliance)
Thomas Heymann (USA)

17:25–17:40

Panel Q&A
All

17:40–17:45

Summary and close
Chair – Nikhil Wagle (USA)
E
SCMID-appointed Chair – Daniel Diekema (USA)

Saturday 10 July, 2021, 13:15–14:15 CEST

COVID-19: out of adversity comes learnings 

13:15–13:20

Welcome and introduction
Chair – Souha Kanj (Lebanon)
ESCMID-appointed Chair – Cansu Cimen (Netherlands)

13:20–13:35

Lessons from history when tackling adversity
Erica Charters (UK)

13:35–13:50

SARS-CoV-2 Variants: epidemiology and transmission
Souha Kanj (Lebanon)

13:50–14:05

Pathogenesis of COVID-19: the role of the virus
Alex Soriano (Spain)

14:05–14:10

Discussion
All

14:10–14:15

Summary and close
Chair – Souha Kanj (Lebanon)
ESCMID-appointed Chair – Cansu Cimen (Netherlands)

Saturday 10 July, 2021, 16:15–18:15 CEST

Piecing together the patient puzzle: navigating the MDR Gram-negative infection treatment paradigm   

16:15–16:20

Welcome and introduction
Chair – Christian Eckmann (Germany)
E
SCMID-appointed Chair – William Hope (UK)

16:20–16:35

Optimising the management of MDR Gram-negative infection: early versus late treatment
Michele Bartoletti (Italy)

16:35–16:55

A spotlight on MDR Pseudomonas aeruginosa: what do the data tell us?
Juan-Pablo Horcajada (Spain)

16:55–17:15

Tackling priority pathogens: the challenge of CRE
Ana Gales (Brazil)

17:15–17:40

Real-world use of ceftazidime‒avibactam*: data from the last four years
Mario Tumbarello (Italy)  

17:40–18:00

Exploring the options: novel therapies and recommendations for MDR Gram-negative infection 
Christian Eckmann (Germany)

18:00–18:10

Panel discussion and Q&A
All

18:10–18:15

Reflection points and close
Chair – Christian Eckmann (Germany)
E
SCMID-appointed Chair – William Hope (UK)

Sunday 11 July, 2021, 13:15–15:15 CEST 

Treating invasive mould disease in an era of complex epidemiology and patient needs

13:15–13:20

Welcome and introduction
Chair – Johan Maertens (Belgium) 
ESCMID-appointed Chair – Ferry Hagen (Netherlands)  

13:20–13:45

Invasive mould disease and COVID-19: what do we need to know?
Alexandre Alanio (France)

13:45–14:10

The diagnostic-driven approach to invasive mould disease in times of medical uncertainty 
Johan Maertens (Belgium)

14:10–14:35

PK/PD considerations and hot topics in antifungal treatment
Roger Bruggemann (Netherlands) 

14:35–15:00

Best-practice approach to the management of invasive mould infections in patients with severe comorbidities: a case study
Malgorzata Mikulska (Italy)

15:00–15:15

Discussion, Q&A and close
All

Sunday 11 July, 2021, 16:15–18:15 CEST

What are the treatment options for CAP and cSSTI in 2021? 

16:15–16:20 

Introduction
Chair – Philippe Montravers (France)
ESCMID-appointed Chair – Gian Maria Rossolini (Italy)

16:20–16:40 

Can we help improve AMS for CAP and cSSTI in the wake 
of COVID-19?
Roman Kozlov (Russia)

16:40–17:00 

How do we manage CAP patients?
Antoni Torres (Spain)

17:00–17:20 

The paediatric pneumonia patient
Susanna Esposito (Italy)

17:20–17:50  

Recommendations for the treatment of cSSTI
Philippe Montravers (France)

17:50–18:10

Q&A
All

18:10–18:15

Close
Chair – Philippe Montravers (France)
E
SCMID-appointed Chair – Gian Maria Rossolini (Italy)